Free shipping on all orders over $ 500

PF-3845

Cat. No. M3525

All AbMole products are for research use only, cannot be used for human consumption.

PF-3845 Structure
Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
1mg USD 30 In stock
5mg USD 55 In stock
10mg USD 95 In stock
25mg USD 185 In stock
50mg USD 310 In stock
100mg USD 495 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

PF-3845 is a potent, selective, and irreversible fatty acid amide hydrolase (FAAH) inhibitor with a Ki of 0.23 μM. Fatty acid amide hydrolase (FAAH) is an enzyme that catalyzes N-acyl ethanolamines (NAEs), including the endocannabinoid arachidonoyl ethanolamide (AEA). Mechanistic and structural studies demonstrated that PF-3845 acts as a covalent inhibitor and carbamylates the active site serine241 of FAAH. PF-3845 covalently binds FAAH on Ser241 at the catalytic site, resulting in prolonged elevation of AEA in the brain and plasma in rats after treatment. Initial experiments indicated that PF-3845 is 10 to 20 times more potent than other FAAH inhibitors and has superior pharmacokinetic properties. PF-3845 significantly and persistently blockes inflammatory pain in rats through a cannabinoid receptor-dependent mechanism. In animal studies, PF-3845 elevated brain anandamide levels for up to 24 hours and produced a marked cannabinoid receptor-dependent reduction in inflammatory pain.

Protocol (for reference only)
Cell Experiment
Cell lines
Preparation method
Concentrations
Incubation time
Animal Experiment
Animal models Male C57BL/6 mice
Formulation PF-3845 is dissolved at 1 mg/ml by sonication and vortexing directly into a solution of 18:1:1 v/v/v saline:emulphor:ethanol.
Dosages 10 mg/kg or 1-30 mg/kg
Administration Administered via i.p. 1 hour before sacrificed by CO2 or oral administration.
Chemical Information
Molecular Weight 456.46
Formula C24H23F3N4O2
CAS Number 1196109-52-0
Solubility (25°C) DMSO 90 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Heng Wang, et al. Rediscovery of PF-3845 as a new chemical scaffold inhibiting phenylalanyl-tRNA synthetase in Mycobacterium tuberculosis

[2] Hye-Jung Ihn, et al. PF-3845, a Fatty Acid Amide Hydrolase Inhibitor, Directly Suppresses Osteoclastogenesis through ERK and NF-κB Pathways In Vitro and Alveolar Bone Loss In Vivo

[3] Heng Wang, et al. Re-discovery of PF-3845 as a new chemical scaffold inhibiting phenylalanyl-tRNA synthetase in Mycobacterium tuberculosis

[4] Hsiao-Jou Cortina Chen, et al. Inhibition of Fatty Acid Amide Hydrolase by PF-3845 Alleviates the Nitrergic and Proinflammatory Response in Rat Hippocampus Following Acute Stress

[5] Andrzej Wasilewski, et al. Fatty acid amide hydrolase (FAAH) inhibitor PF-3845 reduces viability, migration and invasiveness of human colon adenocarcinoma Colo-205 cell line: an in vitro study

Related FAAH Products
JNJ-1661010

JNJ-1661010 is a potent and selective FAAH inhibitor with IC50 of 10 nM (rat) and 12 nM (human), exhibits >100-fold selectivity for FAAH-1 when compared to FAAH-2.

URB597

URB597 is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets.

Biochanin-A

Biochanin A is A naturally occurring fatty acid amide hydrolase (FAAH) inhibitor that inhibits FAAH in mice, rats and humans with FAAH IC50 of 1.8, 1.4 and 2.4 μM, respectively.

FAAH-IN-2

FAAH-IN-2 is a potent FAAH (fatty acid amide hydrolase) inhibitor.

PF 04457845

PF 04457845 is a potent and selective irreversible FAAH inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: PF-3845 supplier, FAAH, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.